AC-262536
Muscle Growth & Body CompositionAlso known as: AC262536, Accadrine
Selective Androgen Receptor ModulatorsResearch phase: PreclinicalRegulatory: Not FDA-approved. Research chemical only. No human clinical trials.
Mechanism
AC-262536 (Accadrine) is a preclinical SARM developed by Acadia Pharmaceuticals with moderate anabolic activity and good tissue selectivity. It shows approximately 66% of testosterone's muscle-building effect with only 27% of its prostate-stimulating activity in animal models.
Technical detail
AC-262536 is a non-steroidal SARM that binds AR with moderate affinity (Ki ~5 nM) and demonstrates partial agonist activity. In castrated rat models, it achieved 66% of the maximal anabolic effect of testosterone propionate on the levator ani with only 27% of the androgenic effect on seminal vesicles, yielding a selectivity index of approximately 2.45:1. It remains in early preclinical evaluation with no progression to human trials.